Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03329014 · ClinicalTrials.gov registry record · Phase 1
A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability
A Phase 1 study, sponsored by Paion UK.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03329014 is a Phase 1 study that has completed, run by Paion UK. The registered enrollment target is 12 participants.
The verdict
NCT03329014, a Phase 1 study, has completed, sponsored by Paion UK.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
A prospective dose escalation, nine period cross-over trial assessing the safety, pharmacokinetics, bioavailability and pharmacodynamics of escalating doses of Remimazolam when administered intranasally as powder and solution in healthy subjects and compared to an intravenous control
Interventions
- DRUG Placebo
- DRUG Remimazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2017-06-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03329014
The ClinicalTrials.gov registry entry for NCT03329014 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Paion UK, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03329014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03329014 about?
NCT03329014 is a clinical study titled "A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability". A prospective dose escalation, nine period cross-over trial assessing the safety, pharmacokinetics, bioavailability and pharmacodynamics of escalating doses of Remimazolam when administered intranasally as powder and solution in healthy subjects and compared to an intravenous control
What is the current status of trial NCT03329014?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-05-15. Estimated completion is 2017-06-14.
What interventions are being tested in trial NCT03329014?
The interventions under investigation include: Placebo (DRUG), Remimazolam (DRUG).
Who is sponsoring clinical trial NCT03329014?
This trial is sponsored by Paion UK, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.